410 related articles for article (PubMed ID: 32646867)
1. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.
Sewell HF; Agius RM; Kendrick D; Stewart M
BMJ; 2020 Jul; 370():m2722. PubMed ID: 32646867
[No Abstract] [Full Text] [Related]
2. Audio Interview: Operation Warp Speed and Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Aug; 383(9):e79. PubMed ID: 32846078
[No Abstract] [Full Text] [Related]
3. Audio Interview: Capitalizing on Immune Responses to Covid-19.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 May; 382(21):e93. PubMed ID: 32433859
[No Abstract] [Full Text] [Related]
4. Immunotherapeutic approaches to curtail COVID-19.
Owji H; Negahdaripour M; Hajighahramani N
Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
[TBL] [Abstract][Full Text] [Related]
5. Possible treatment of Covid-19 with a therapeutic vaccine.
Myint A; Jones T
Vet Rec; 2020 Apr; 186(13):419. PubMed ID: 32245869
[No Abstract] [Full Text] [Related]
6. Antibody therapies could be a bridge to a coronavirus vaccine - but will the world benefit?
Ledford H
Nature; 2020 Aug; 584(7821):333-334. PubMed ID: 32782402
[No Abstract] [Full Text] [Related]
7. COVID-19: Main therapeutic options.
Hachfi W; Ben Lasfar N
Tunis Med; 2020 Apr; 98(4):299-303. PubMed ID: 32395792
[No Abstract] [Full Text] [Related]
8. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
Shih HI; Wu CJ; Tu YF; Chi CY
Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623
[TBL] [Abstract][Full Text] [Related]
9. COVID-19: The Need for Immunoprevention at Industrial Scale.
Halstead SB
Am J Trop Med Hyg; 2020 Jun; 102(6):1151. PubMed ID: 32274985
[No Abstract] [Full Text] [Related]
10. Why should we use convalescent plasma for COVID-19?
Franchini M
Eur J Intern Med; 2020 Jul; 77():150-151. PubMed ID: 32425365
[No Abstract] [Full Text] [Related]
11. [Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019].
Yan CX; Li J; Shen X; Luo L; Li Y; Li MY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 51(2):139-145. PubMed ID: 32220178
[TBL] [Abstract][Full Text] [Related]
12. Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2020 Apr; 382(16):e58. PubMed ID: 32320592
[No Abstract] [Full Text] [Related]
13. Monoclonal Antibodies for Prevention and Treatment of COVID-19.
Marovich M; Mascola JR; Cohen MS
JAMA; 2020 Jul; 324(2):131-132. PubMed ID: 32539093
[No Abstract] [Full Text] [Related]
14. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
Lee WS; Wheatley AK; Kent SJ; DeKosky BJ
Nat Microbiol; 2020 Oct; 5(10):1185-1191. PubMed ID: 32908214
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: endgames.
The Lancet Infectious Diseases
Lancet Infect Dis; 2020 May; 20(5):511. PubMed ID: 32311325
[No Abstract] [Full Text] [Related]
16. The possible of immunotherapy for COVID-19: A systematic review.
AminJafari A; Ghasemi S
Int Immunopharmacol; 2020 Jun; 83():106455. PubMed ID: 32272396
[TBL] [Abstract][Full Text] [Related]
17. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population.
Yi Z; Ling Y; Zhang X; Chen J; Hu K; Wang Y; Song W; Ying T; Zhang R; Lu H; Yuan Z
Emerg Microbes Infect; 2020 Dec; 9(1):1988-1996. PubMed ID: 32844713
[No Abstract] [Full Text] [Related]
18. Convalescent Plasma and COVID-19.
Malani AN; Sherbeck JP; Malani PN
JAMA; 2020 Aug; 324(5):524. PubMed ID: 32530454
[No Abstract] [Full Text] [Related]
19. Challenges of Convalescent Plasma Therapy on COVID-19.
Zhao Q; He Y
J Clin Virol; 2020 Jun; 127():104358. PubMed ID: 32305026
[No Abstract] [Full Text] [Related]
20. Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma.
Lindholm PF; Ramsey G; Kwaan HC
Semin Thromb Hemost; 2020 Oct; 46(7):796-803. PubMed ID: 32526774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
